Other News To Note
• BioAlliance Pharma SA, of Paris, said it started its Phase III ReLive trial testing Livatag (doxorubicin Transdrug) in nearly 400 patients with hepatocellular carcinoma, who are resistant or intolerant to Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG).